Understanding the costs of Ozempic vs Mounjaro vs Wegovy is crucial for patients considering these weight management and diabetes medications in the UK. All three are injectable incretin mimetics that regulate appetite and blood glucose, but they differ in licensing, availability, and price. Ozempic and Mounjaro are primarily licensed for type 2 diabetes, whilst Wegovy is specifically approved for chronic weight management. NHS access is strictly criteria-based and often limited, whilst private prescription costs range from £150 to £350 monthly, plus consultation fees. This article examines the comparative costs, NHS eligibility, private options, insurance coverage, and long-term value considerations to help patients and clinicians make informed decisions.

Understanding Ozempic, Mounjaro and Wegovy: What They Are

Ozempic, Mounjaro and Wegovy are injectable medications that have gained considerable attention for their effects on weight management and glycaemic control. All three belong to a class of drugs known as incretin mimetics, which work by mimicking hormones naturally produced in the gut to regulate appetite and blood sugar levels.

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed for the treatment of type 2 diabetes mellitus. It works by stimulating insulin secretion when blood glucose is elevated, suppressing glucagon release, and slowing gastric emptying. These mechanisms help improve glycaemic control and often result in weight loss as a secondary benefit. Ozempic is administered once weekly via subcutaneous injection. Using Ozempic solely for weight loss represents off-label prescribing.

Wegovy contains the same active ingredient as Ozempic—semaglutide—but is specifically licensed for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. Wegovy is prescribed at higher doses than Ozempic (titrated up to 2.4 mg weekly) and is intended as an adjunct to a reduced-calorie diet and increased physical activity.

Mounjaro (tirzepatide) represents a newer therapeutic approach, functioning as a dual agonist of both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual mechanism may offer enhanced effects on weight reduction and metabolic control compared to GLP-1 agonists alone. Mounjaro is licensed in the UK for both type 2 diabetes and weight management (titrated up to 10-15 mg weekly). Like the others, it requires once-weekly subcutaneous administration. Understanding these distinctions is essential when considering cost, availability, and suitability for individual patients.

NHS Availability and Prescription Criteria in the UK

Access to these medications via the NHS is governed by strict eligibility criteria established by the National Institute for Health and Care Excellence (NICE) and individual Integrated Care Boards (ICBs). These criteria reflect both clinical evidence and cost-effectiveness considerations within the publicly funded healthcare system.

Ozempic is available on NHS prescription for adults with type 2 diabetes mellitus who meet specific criteria outlined in NICE guideline NG28. GLP-1 receptor agonists like Ozempic are typically recommended when other treatments haven't adequately controlled blood glucose, with specific consideration for patients with higher BMI (≥35 kg/m², or ≥30 kg/m² in certain ethnic groups) or those for whom weight loss would benefit other obesity-related comorbidities. Treatment continuation requires demonstration of beneficial response at 6 months, including an HbA1c reduction of at least 11 mmol/mol (1%) and weight loss of at least 3%.

Wegovy received NICE approval (TA875) for NHS use in chronic weight management, but availability remains limited. Eligibility is restricted to adults with a BMI ≥35 kg/m² (or ≥32.5 kg/m² in certain ethnic groups) and at least one weight-related comorbidity, or BMI ≥30 kg/m² with specific conditions. Treatment must be initiated by specialist weight management services, is typically time-limited (up to 2 years), and requires demonstration of at least 5% weight loss at 6 months to continue. Due to supply constraints, many ICBs have implemented waiting lists or restricted prescribing.

Mounjaro is available on NHS prescription for type 2 diabetes under similar criteria to Ozempic. While it holds a UK marketing authorisation for weight management, NHS funding for this indication depends on NICE guidance and local ICB formulary decisions, with significant regional variation. Patients seeking these medications through the NHS should consult their GP about referral pathways, including potential referral to Tier 3 specialist weight management services where appropriate.

Private Prescription Costs: Ozempic vs Mounjaro vs Wegovy

For patients who do not meet NHS criteria or face lengthy waiting times, private prescription offers an alternative route to access these medications, though at considerable personal expense. Private costs vary significantly depending on the prescribing clinic, pharmacy, and dosage regimen. Prices quoted below are approximate and may change (as of April 2024).

Ozempic private prescription costs typically range from £150 to £200 per month for maintenance doses (0.5 mg or 1 mg weekly). Some private clinics offer package deals that include initial consultation, ongoing monitoring, and medication supply, which may cost between £200 and £300 monthly. Patients should note that Ozempic is licensed for diabetes, and private prescribing for weight loss alone represents off-label use. Due to ongoing supply constraints, healthcare professionals are advised not to initiate Ozempic for off-label weight management.

Wegovy private costs are generally higher, reflecting its specific weight management licensing and higher dosage formulation. Monthly costs typically range from £200 to £300, with some providers charging up to £350 depending on the dose tier (ranging from 0.25 mg starter dose to 2.4 mg maintenance dose). The titration schedule requires several months to reach the therapeutic dose, and total treatment duration often extends 12–24 months for optimal benefit, representing a substantial financial commitment.

Mounjaro private prescription costs are comparable to or slightly higher than Wegovy, typically ranging from £229 to £350 per month. As the newest option with dual-agonist properties, Mounjaro may command premium pricing in the private market. Availability through private clinics is increasing, though supply can be variable.

All three medications require ongoing prescriber oversight, including regular consultations (often monthly or quarterly), which incur additional fees ranging from £50 to £150 per appointment. Patients should budget for comprehensive costs including consultations, blood tests, and medication over the intended treatment period, which may total £3,000 to £6,000 annually. It is essential to use General Pharmaceutical Council (GPhC) registered pharmacies and Care Quality Commission (CQC) regulated providers to ensure medication authenticity and patient safety.

Insurance Coverage and Patient Access Schemes

Private medical insurance (PMI) coverage for Ozempic, Mounjaro, and Wegovy varies considerably between insurers and policy types. Most standard PMI policies in the UK do not routinely cover medications for weight management, as obesity treatment is often excluded or subject to specific endorsements. However, coverage may be available when these medications are prescribed for type 2 diabetes as part of a recognised treatment pathway.

Patients with comprehensive PMI policies should review their specific terms regarding endocrine conditions and diabetes management. Some insurers may cover Ozempic or Mounjaro when prescribed by an endocrinologist for diabetes with documented inadequate control on standard therapies. Pre-authorisation is typically required, and insurers may impose restrictions on treatment duration or require evidence of clinical benefit at review intervals. Wegovy, being specifically licensed for weight management rather than diabetes, faces more limited insurance coverage, even when prescribed for patients with obesity-related comorbidities.

Patient access schemes and manufacturer support programmes are not widely available in the UK for these medications in the same way they exist for some specialist drugs. However, patients prescribed these medications on the NHS may benefit from the standard NHS prescription charge (currently £9.90 per item in England, with prescriptions free in Scotland, Wales, and Northern Ireland). Those requiring multiple prescriptions may benefit from NHS prescription prepayment certificates, which cap annual costs.

Some private clinics offer payment plans or subscription models that spread costs over several months, making treatment more financially accessible. Additionally, pharmaceutical manufacturers occasionally provide starter packs or dose-titration support through healthcare providers, though these are typically limited to NHS or clinical trial settings. Patients considering private treatment should enquire directly with prescribing clinics about available payment options, and those with PMI should obtain written confirmation of coverage before commencing treatment to avoid unexpected costs.

Cost-Effectiveness and Long-Term Value Considerations

When evaluating the cost of Ozempic, Mounjaro, and Wegovy, it is essential to consider cost-effectiveness beyond the immediate medication price. NICE assessments examine the quality-adjusted life years (QALYs) gained and potential healthcare savings from preventing or managing obesity-related complications such as type 2 diabetes, cardiovascular disease, and osteoarthritis.

For type 2 diabetes management, both Ozempic and Mounjaro have demonstrated cost-effectiveness within NHS thresholds when prescribed according to NICE criteria. The medications' ability to improve glycaemic control, promote weight loss, and potentially reduce cardiovascular risk can offset costs through reduced need for additional diabetes medications, fewer hospital admissions, and prevention of long-term complications. For semaglutide, cardiovascular benefits have been demonstrated in the SUSTAIN-6 trial for patients with type 2 diabetes and established cardiovascular disease.

Wegovy's cost-effectiveness for weight management is more complex. NICE's positive recommendation (TA875) was based on evidence showing significant weight loss (average 10–15% body weight in the STEP clinical trials) and improvements in cardiometabolic risk factors. However, the high acquisition cost means cost-effectiveness is most favourable in patients with higher BMI and multiple comorbidities. Treatment is typically time-limited (up to 2 years), with the expectation that patients maintain weight loss through sustained lifestyle changes. Treatment should be discontinued if a patient has not lost at least 5% of their initial body weight after 6 months at the maintenance dose.

Long-term value considerations include the need for ongoing lifestyle modification support, potential for weight regain after discontinuation, and individual response variability. Not all patients achieve clinically significant weight loss, and treatment should be discontinued if inadequate response is observed according to NICE and product licence criteria. Patients should discuss realistic expectations, treatment duration, and total costs with their healthcare provider. For those funding treatment privately, the financial commitment must be weighed against alternative approaches such as structured weight management programmes, dietetic support, or, in appropriate cases, bariatric surgery, which may offer more durable outcomes despite higher upfront costs.

Patients and healthcare professionals should report any suspected side effects via the MHRA Yellow Card scheme.

Frequently Asked Questions